Want to see AU:XEN full AI Analyst Report?
AuMake Ltd. (XEN) AI Stock Analysis
Top Page
AuMake Ltd.
(ASX:XEN)
The score is driven primarily by weak financial performance: sharp FY2026 revenue deterioration, persistent losses (including a gross loss), ongoing negative operating/free cash flow, and materially higher leverage as equity fell. Valuation provides limited support due to negative earnings and no stated dividend yield, while technical analysis is neutral because key indicators were not provided.
AuMake Ltd. (XEN) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 7.73M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -3.3
- Beta (1Y)
- -0.60
- Revenue Growth
- -49.44%
- EPS Growth
- 7.14%
- Country
- Australia
- Employees
- 0
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Department Stores
AuMake Ltd. Business Overview & Revenue Model
Company Description
Xenitra Limited operates an e-commerce platform, facilitating the online sale of a broad spectrum of products throughout Australia, Hong Kong, Mainland China, and New Zealand. Its extensive inventory features a wide selection of beverages, both alcoh...
How the Company Makes Money
null
AuMake Ltd. Financial Statement Overview
Summary
Financial statements indicate significant weakness: FY2026 revenue fell ~40% vs FY2025, profitability is structurally negative (including a FY2026 gross loss), operating and free cash flow are negative across all years provided, and leverage spiked sharply as equity declined (debt-to-equity roughly 4.8x). A partial offset is improved cash burn in FY2026 vs FY2025, but overall funding and execution risk remain elevated.
Income Statement
18Very NegativeBalance Sheet
28NegativeCash Flow
22Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.11M | 20.11M | 39.77M | 25.87M | 2.67M | 6.01M |
| Gross Profit | -2.25M | -2.25M | 968.93K | 843.62K | 60.17K | -3.61M |
| EBITDA | -5.47M | -5.47M | -3.39M | -5.85M | -2.11M | -4.78M |
| Net Income | -5.18M | -5.18M | -3.48M | -6.28M | -3.03M | -6.07M |
Balance Sheet | ||||||
| Total Assets | 4.44M | 4.44M | 8.30M | 4.37M | 6.37M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 3.16M | 3.16M | 1.72M | 2.03M | 1.55M | 3.04M |
| Total Debt | 1.21M | 1.21M | 1.16M | 2.19M | 0 | 520.24K |
| Total Liabilities | 4.26M | 4.26M | 5.64M | 3.80M | 1.26M | 5.98M |
| Stockholders Equity | 252.00K | 252.00K | 2.55M | 524.74K | 5.11M | 4.18M |
Cash Flow | ||||||
| Free Cash Flow | -1.14M | -1.14M | -4.26M | -2.84M | -3.46M | -5.35M |
| Operating Cash Flow | -1.13M | -1.13M | -4.26M | -2.66M | -3.46M | -4.64M |
| Investing Cash Flow | 0 | 0 | -38.83K | -318.20K | -192.52K | 589.87K |
| Financing Cash Flow | 2.58M | 2.58M | 3.93M | 3.58M | 2.00M | 2.59M |
AuMake Ltd. Peers Comparison
Overall Rating
AU:KGN69Neutral
AU:DSK58Neutral
AU:TPW51Neutral
AU:ADH49Neutral
AU:MYR45Neutral- AU:XEN40.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:KGN | 69Neutral | AUD 376.41M | 34.65 | 23.74% | 4.06% | 4.64% | ― |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| AU:DSK | 58Neutral | AUD 42.65M | 7.99 | 14.55% | 8.18% | 8.43% | 23.06% |
| AU:TPW | 51Neutral | AUD 615.37M | 147.90 | 3.54% | ― | 10.63% | -62.61% |
| AU:ADH | 49Neutral | AUD 239.78M | -6.11 | -19.53% | 8.61% | 3.83% | -251.57% |
| AU:MYR | 45Neutral | AUD 345.55M | -1.28 | -36.45% | 7.50% | 11.98% | 3.09% |
| AU:XEN | 41Neutral | AUD 9.39M | -3.33 | -549.71% | ― | -49.44% | 7.14% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:XEN | AuMake Ltd. | ― | ― | ― | |
| AU:KGN | Kogan.com Ltd. | 3.94 | 0.93 | 30.85% | |
| AU:TPW | Temple & Webster Group Ltd | 5.28 | -18.45 | -77.75% | |
| AU:ADH | Adairs Ltd. | 1.33 | -0.54 | -28.92% | |
| AU:MYR | Myer Holdings Limited | 0.20 | -0.18 | -47.92% | |
| AU:DSK | Dusk Group Ltd. | 0.69 | -0.16 | -18.74% |
AuMake Ltd. Corporate Events
Xenitra Confirms Compliance on New Share Issue Under Corporations Act
Xenitra Limited has issued fully paid ordinary shares without a prospectus, relying on provisions that allow certain share issues without formal disclosure under the Corporations Act. The company has confirmed to investors that it remains compliant w...
Xenitra Seeks ASX Quotation for 259 Million New Shares
Xenitra Limited has applied to the Australian Securities Exchange for quotation of 259,000,002 ordinary fully paid shares, with an issue date of 1 September 2026. The new quotation will expand the company’s listed share base, potentially enhanc...
Xenitra Files Updated Corporate Governance Statement and Appendix 4G with ASX
Xenitra Limited has lodged its corporate governance statement and a completed Appendix 4G with the ASX for the year ended 30 June 2026, confirming compliance with Listing Rules 4.10.3 and 4.7.3. The statement, approved by the board as at 31 August 20...
Xenitra Revenue Halves as Annual Loss Deepens and NTA Slides
Xenitra Limited reported a sharp deterioration in its financial results for the year ended 30 June 2026, with revenue from ordinary activities falling 49.4% to $20.1 million and the net loss attributable to owners widening 48.9% to $5.2 million. The...
Xenitra Plans Major Share and Option Issue on ASX
Xenitra Limited has notified the ASX of a proposed securities issue comprising up to 515,000,000 ordinary fully paid shares and 280,000,000 options exercisable at $0.004 and expiring in April 2028. The issue, structured as a placement or other type o...
Xenitra Raises A$1.5m to Drive High-Margin Healthcare and Digital Commerce Growth
Xenitra Limited has raised A$1.5 million via a placement of 500 million new shares at A$0.003 to sophisticated and professional investors, with free-attaching options subject to shareholder approval. The capital will be used as working capital to exp...
Xenitra Seeks ASX Trading Halt Ahead of Material Capital Raising
Xenitra Limited, an ASX-listed company, participates in Australia’s capital markets as a publicly traded entity. Its operations and investor relations are governed by ASX listing rules and compliance requirements, which shape how material corpo...
Xenitra expands into specialised medical nutrition with A$5m FSMP deal
Xenitra’s Hong Kong-based subsidiary Fukang has signed a three-year framework purchase agreement with Joy Charm Limited to supply Food for Special Medical Purposes products, targeting aggregate procurement of A$5 million. The deal extends Xenit...
Xenitra outlines investor information and broad risk warnings
Xenitra Limited has issued an investor presentation outlining general information on its current activities and reiterating that the document is for information purposes only, not a prospectus or formal offer of securities. The company emphasises tha...
Xenitra Delivers Cash-Flow Turnaround as OPAL and OTC Strategies Take Hold
Xenitra Limited, an Australian health products company listed on the ASX, is reshaping its business around three pillars: nutritionals, over-the-counter medicines and OPAL-tokenised sales. The firm is reducing exposure to low-margin, working-capital-...
Xenitra Secures $12m OTC Deal to Drive China Healthcare Push
Xenitra Limited has signed a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading, one of China’s leading omnichannel distributors across e-commerce platforms and retail pharmacies. The deal, executed v...
Xenitra Schedules Investor Webinar to Highlight Asian Growth Strategy
Xenitra Limited has invited investors and shareholders to participate in an online webinar scheduled for 1:30 p.m. on Thursday, 11 June, signalling an effort to deepen engagement with the market. The session is expected to provide investors with insi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026